White Coat Hypertension & Cardiovascular Outcomes.

Autor: Townsend RR; Perelman School of Medicine at the University of Pennsylvania, Renal Electrolyte and Hypertension Division, 122 Founders Building 3400 Spruce Street, Philadelphia, PA, United States. townsend@upenn.edu., Cohen JB; Perelman School of Medicine at the University of Pennsylvania, Renal Electrolyte and Hypertension Division, 122 Founders Building 3400 Spruce Street, Philadelphia, PA, United States.
Jazyk: angličtina
Zdroj: Current hypertension reports [Curr Hypertens Rep] 2024 Oct; Vol. 26 (10), pp. 399-407. Date of Electronic Publication: 2024 May 18.
DOI: 10.1007/s11906-024-01309-0
Abstrakt: Purpose of Review: This review aims to inform the reader of the complexity of blood pressure responses when comparing blood pressure measured in the medical environment to that outside the medical environment. In addition, we summarize what is known about current predictors of white coat hypertension, reevaluate the relationship of white coat hypertension to cardiovascular outcomes, and provide some clinical guidance on management.
Recent Findings: Differences in outcomes exist when white coat effect occurs in unmedicated people versus the white coat effects in those on antihypertensive therapy. White coat hypertension is relatively common, carries a small but definite increase in cardiovascular risk, and is prone to conversion to sustained hypertension. Future research will hopefully tease out the roles of ancillary findings that characterize a white coat hypertensive (like modest elevations in creatinine, glucose and triglycerides) in the elevated cardiovascular risk, and test the effectiveness of mitigation strategies in these patients.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: